CURRENTLY SOLD OUT
Best-selling in Other Non-Fiction
Save on Other Non-Fiction
- £24.44Trending at £26.04
- £23.12Trending at £34.99
- £10.01Trending at £10.67
- £24.23Trending at £25.25
- £17.16Trending at £22.74
- £21.65Trending at £24.06
- £4.99Trending at £6.16
About this product
- DescriptionThis authoritative and comprehensive book makes the reader familiar with the processes of bringing orphan drugs to the global market. There are between 5,000 and 7,000 rare diseases and the number of patients suffering from them is estimated to be more than 50 million in the US and Europe.
- Author BiographyElizabeth Hernberg-Stahl, M.Sc, is founder of Late Phase Solutions Europe AB, based in Sweden; it is an independent consultancy focusing on providing strategic and operational guidance on late phase drug development as well as guidance on processes and activities related to orphan drug development and market access. The author has more than thirty years experience from the international biotech and pharmaceutical industry (20 of which were in the orphan drugs area). During her 10 years at TKT/Shire HGT Elizabeth was responsible for developing and establishing the Global Outcome Survey Department, which manages global patient registries. Elizabeth was also member of the Shire HGT European Management Team and the Global Medical Affairs Leadership Team. Before joining Shire HGT/TKT Europe-5S, Elizabeth held a similar position for 8 years at Pharmacia/Pfizer where she established and managed a global patient registry KIMS on the rare condition adult GHD and the outcome of growth hormone treatment. Elizabeth has published numerous papers and is a frequent speaker at several congresses on topics related to orphan rare diseases. Miroslav Reljanovic, MD, MSc, is a board-certified neurologist. Whilst practising as a physician in a large WHO Collaborating Centre in Zagreb, he was the clinical investigator in numerous Phase II and III studies in the field of neurology and a consultant to various pharmaceutical companies. In 1997, Miro founded Ergomed contract research organization (CRO) and he introduced the novel Study Site Coordination model as an intrinsic part of the conduct of clinical studies. This model became a landmark of the Ergomed approach to clinical research which is paramount to provide high quality trial data in very demanding areas like oncology, neurology, and orphan diseases including rare cancers. Miro has also successfully introduced the first European innovative co-development business model and he has completed several transactions with European and North American listed biopharmaceutical companies. Together with co-founder Elliot Brown, MB, MRCGP, FFPM, a well known international expert in drug safety, Miro started PrimeVigilance in 2008, which soon became a leading specialist vendor of contracted pharmacovigilance services to the pharmaceutical industry. Through a strategic partnership with Elizabeth Hernberg-Stahl, Miro established a specific division at Ergomed, focusing on providing assistance and support to biotechnology and drug industries, clinicians, and researchers, to facilitate the development of candidate drugs for rare diseases in this challenging field.
- Author(s)Elizabeth Hernberg-Stahl,Miroslav Reljanovic
- PublisherElsevier Science & Technology
- Date of Publication31/10/2013
- GenreIndustrial Chemistry & Manufacturing
- Series TitleWoodhead Publishing Series in Biomedicine
- Series Part/Volume NumberNo. 46
- Place of PublicationCambridge
- Country of PublicationUnited Kingdom
- ImprintWoodhead Publishing Ltd
- Content Noteblack & white illustrations
- Weight650 g
- Width156 mm
- Height234 mm
- Spine19 mm
This item doesn't belong on this page.
Thanks, we'll look into this.